



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2023-24/49

July 24, 2023

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

Dear Sir/Madam,

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Sub: Newspaper Publication
Ref: Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

In accordance with Regulation 47 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 please find enclosed newspaper publication of Standalone and Consolidated Financial Results for the quarter ended June 30, 2023, published in the following newspapers:

- 1) Financial Express (English)
- 2) Mumbai Lakshadweep (Marathi)

Kindly take the same on record.

Thanking you,

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: A54527

CREDIT SUBSTITUTES ROSE 18% Y-O-Y TO ₹3.6 TRN Kotak Mahindra Bank PAT rises 67% Y-o-Y on strong loan growth

Provisions for tax rose to ₹1,133 cr in the June quarter


AJAY RAMANATHAN
Mumbai, July 22

THE NET PROFIT of Kotak Mahindra Bank rose 67% year-on-year (y-o-y) in the June quarter due to a growth in its loan book. The bank posted a bottom-line of ₹3,452 crore in April-June, higher than the ₹3,219 crore estimated by Bloomberg.

But, provisions for tax rose to ₹1,133 crore in the June quarter from ₹689 crore in the March quarter due to which, the bottom-line was slightly lower on a sequential basis. On a consolidated basis, net profit was ₹4,150 crore. The private bank's advances rose 19% y-o-y to ₹3.4 trillion as on June 30. Customer assets, which comprises advances and credit substitutes rose 18% y-o-y to ₹3.6 trillion.

Specifically, customer assets were aided by a 91% y-o-y rise in the retail microfinance segment, a 67% y-o-y rise in the credit card segment. Personal and business loans, consumer durable segment also rose 43% y-o-y. Home loans and loan against property rose 18% y-o-y.

Unsecured retail advances rose to 10.7% of overall advances as on June 30 from 7.9% of overall advances a year ago. Corporate banking segment reported 9% y-o-y to ₹77,569 crore as on June 30. "While overall loan



'Arjuna's eye taken out of context'

COMMENTING ON A recent media report that the Reserve Bank of India (RBI) was miffed over CEO Uday Kotak's reference to 'Arjuna's eye' in a letter to shareholders, Dipak Gupta noted that the letter was being taken out of context.

"Arjuna's eye is a common phrase that all of us use to mean focused attention on something. Arjuna's eye is actually about managing risks. The focus of the paragraph was about how we improve our risk management capability, both from a regulatory and a policy framework," Gupta said. "Look at it as risk man-

agement and not in any other context. We are talking about Amrit Kalal by 2047. Unless we create this risk management capacity, how we make that happen. That was the framework of the piece," he added.

In line with trends in the broader banking industry, the bank's current account savings account ratio (CASA) fell to 49% as on June 30 from 58.1% a year ago. The bank's net interest margin rose to 5.57% in the June quarter from 4.92% a year ago. "Margins have moved up in the last three-to-four quarters as interest rates have gone up. The cost of funds takes time to catch up. As the cost of funds keep moving up, the margins will tend to get compressed. They will normalise over a period of time," joint MD Dipak Gupta said. The bank's gross non-performing asset ratio fell to 1.77% as on June 30 from 2.24% a year ago. Net non-performing asset ratio fell to 0.40% as on June 30 from 0.62% a year ago.

The bank witnessed slips pages worth ₹1,205 crore in the June quarter, lower than the ₹1,435 crore a year ago. Recoveries and upgrades were ₹692 crore in the quarter under review.

growth in the first quarter is typically softer, we maintain that we should be targeting 1.5-2 times the nominal GDP of the economy as our growth.

That would take us to a num-

Aarti Drugs Ltd.

Registered Office: Plot No. N-198, MIDC, Tarapur, Village Pamtembhi, Dist. Palghar - 401 506, Maharashtra CIN: L37060MH1984PLC055433, Email ID: investorrelations@aaridrugs.co.in, Website: www.aaridrugs.co.in

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

PARTICULARS	Standalone				Consolidated			
	Quarter Ended		Year Ended		Quarter Ended		Year Ended	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023	30.06.2023	31.03.2023	30.06.2022	31.03.2023
(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)	(Audited)
Total income	59,228	69,734	55,144	2,50,020	66,171	74,328	62,222	2,71,825
Net profit for the period (before tax, exceptional and/or extraordinary items)	5,304	6,942	3,625	20,481	6,353	7,328	4,803	22,418
Exceptional items	-	-	-	-	-	-	-	-
Net profit for the period after Tax (after exceptional and/or extraordinary items)	3,954	5,317	2,635	15,281	4,797	5,618	3,478	16,636
Other Comprehensive Income (after tax)	-	(142)	-	(142)	-	(150)	-	(150)
Total Comprehensive Income for the period	3,954	5,175	2,635	15,139	4,797	5,468	3,478	16,486
Weighted average number of equity shares used for computing earning per share (Face Value of Rs.10 each)	9,260	9,260	9,260	9,260	9,260	9,260	9,260	9,260
Earning per equity share (in Rs.) (not annualised)	9,260	9,260	9,260	9,260	9,260	9,260	9,260	9,260
(a) Basic	4.27	5.74	2.85	16.50	5.18	6.07	3.76	17.97
(b) Diluted	4.27	5.74	2.85	16.50	5.18	6.07	3.76	17.97

Notes:

- The above results for the quarter ended 30th June, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 21st July, 2023.
- Company has only one business segment i.e. pharmaceuticals.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aaridrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

Place : Mumbai
Date : 21st July, 2023

FOR AARTI DRUGS LIMITED
Sd/-
Prakash M. Patil
Chairman, Managing Director & CEO

Paytm ONE 97 COMMUNICATIONS LIMITED

CIN: L72200DL2000PLC108985

Registered Office: First Floor, Devika Tower, Nehru Place, New Delhi 110 019, India;
Tel: +91 11 2628 0280; Website: www.paytm.com
Corporate Office: Paytm Corporate Office, One Skymark, Tower-D, Plot No. H-10B, Sector-98, Noida 201304, Uttar Pradesh, India,
Tel: +91 120 4770770; Fax: +91 120 4770771; E-mail: compliance.officer@paytm.com

I. Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2023

Sr. No.	Particulars	Quarter Ended				Year Ended	
		June 30, 2023		March 31, 2023			
		(Unaudited)	(Audited)	(Unaudited)	(Audited)		
1	Total income from operations (including other income)	24,642	24,646	17,816	84,000		
2	Loss for the period/year before tax	(3,540)	(1,682)	(6,406)	(17,429)		
3	Loss for the period/year after tax	(3,584)	(1,675)	(6,454)	(17,765)		
4	Total comprehensive income/(loss) for the period/year (after tax)	(4,532)	(1,689)	(7,165)	(15,683)		
5	Equity share capital	634	634	649	634		
6	Other equity				1,29,522		
7	Earnings per share (₹ per share of ₹1/- each)	(6)	(3)	(10)	(27)		
	Basic*	(6)	(3)	(10)	(27)		
	Diluted*	(6)	(3)	(10)	(27)		
	*Not annualised for quarters						

II. Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2023

Sr. No.	Particulars	Quarter Ended				Year Ended	
		June 30, 2023		March 31, 2023			
		(Unaudited)	(Audited)	(Unaudited)	(Audited)		
1	Total income from operations (including other income)	19,720	19,360	13,467	64,271		
2	Loss for the period/year before tax (after exceptional items)	(3,328)	(2,033)	(6,280)	(18,558)		
3	Loss for the period/year after tax (after exceptional items)	(3,328)	(2,033)	(6,280)	(18,558)		

Notes:

- The above are extract of the detailed format of Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The full format of financial results are available on the stock exchange websites (www.nseindia.com and www.bseindia.com) and on the Company's website (www.paytm.com).
- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on July 21, 2023.
- The Statement includes the results for the quarter ended March 31, 2023, being the balancing figure between audited figures in respect of the full financial year 2022-23 and the published unaudited year to date figures up to the third quarter of the financial year 2022-23 which were subject to limited review.


For One 97 Communications Limited

Sd/-
Vijay Shekhar Sharma
Chairman, Managing Director and CEO

Place: New Delhi
Date: July 21, 2023



Designed and Made-In-India for the World



Extract of Unaudited Consolidated Results for the quarter ended June 30, 2023				
Sl. No.	Particulars	Quarter ended June 30, 2023	Year ended March 31, 2023	Quarter ended June 30, 2022

